The CCH-induced Ca
2+ increase required release from intracellular stores.
Figure 3Ashows that after application of the irreversible SERCA pump inhibitor, thapsigargin (TG), which generates an increase in Ca
2+ followed by depletion of intracellular Ca
2+ stores, the response to CCH was completely eliminated.
Figure 3Bdemonstrates the involvement of the PLC-dependent metabotropic receptor pathway in the CCH-induced Ca
2+ increase. Application of the PLC blocker U73122 blocked the CCH-activated Ca
2+ increase in the presence of intact intracellular Ca
2+ stores. However, subsequent application of the reversible SERCA pump inhibitor cyclopiazonic acid (CPA) was still able to initiate Ca
2+ release from stores to produce a sustained Ca
2+ increase in the presence of U73122. The bar graph in
Figure 3Cshows the mean CCH-activated Ca
2+ increase measured in the absence of drug (control;
n = 12), in the presence of 10 μM of the L-type Ca
2+ channel blocker nifedipine (
n = 9), and of the TRP channel blockers La
3+ (
n = 16; 100 μM), 2-APB (
n = 3; 100 μM), Gd
3+ (
n = 16; 100 μM), ruthenium red (
n = 9; 20 μM), and flufenamic acid (
n = 8; 100 μM). The CCH-activated Ca
2+ increase was not significantly affected by block of L-type voltage-dependent Ca
2+ channels or ruthenium red, but it was reduced by La
3+ (
P < 0.01), 2-APB (
P < 0.01), Gd
3+ (
P < 0.01), and flufenamic acid (
P < 0.01). The bar graph in
Figure 3Dshows the mean Ca
2+ increase in response to 50 μM of the DAG derivative 1-oleyl-2-acetyl-sn-glycerol (OAG), which has been shown to directly activate some TRPC channels, including TRPC3 and TRPC6,
27 28 applied alone or coapplied with 1 μM CCH. The mean response in the absence of drug (0.1% DMSO control;
n = 8) and to 1 μM CCH in the absence of OAG is also shown. OAG was able to increase Müller cell Ca
2+ compared with control (
P < 0.0001) when applied alone. Furthermore, coapplication of OAG with CCH produced an increase in Ca
2+ that was greater than that seen with 1 μM CCH alone (
P < 0.001). This suggests that DAG analogues, acting through non–store-dependent mechanisms, together with agonist-activated IP3-dependent release from intracellular Ca
2+ stores, can give rise to enhanced Ca
2+ entry.